|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:ATCCode
|
gptkb:G04BE03
|
|
gptkbp:bioavailability
|
40%
|
|
gptkbp:CASNumber
|
gptkb:169590-42-5
|
|
gptkbp:contraindication
|
Nitrate medication
Severe cardiovascular disorders
|
|
gptkbp:developer
|
gptkb:Pfizer
|
|
gptkbp:drugClass
|
gptkb:PDE5_inhibitor
|
|
gptkbp:eliminationHalfLife
|
3–5 hours
|
|
gptkbp:excretion
|
Urine
Feces
|
|
gptkbp:hasInChIKey
|
3M7OB98Y7H
|
|
gptkbp:hasMolecularFormula
|
C22H30N6O4S
|
|
gptkbp:hasPatentExpiry
|
2013 (US)
|
|
gptkbp:hasSMILES
|
CCCN1C2=C(C=N1)N(C=N2)C3=CC(=CC=C3S(=O)(=O)N4CCN(CC4)C)OCC
|
|
gptkbp:hasUNII
|
3M7OB98Y7H
|
|
gptkbp:indication
|
Erectile dysfunction
Pulmonary arterial hypertension
|
|
gptkbp:IUPACName
|
gptkb:1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine
|
|
gptkbp:legalStatus
|
Prescription only
|
|
gptkbp:mechanismOfAction
|
Inhibits phosphodiesterase type 5 (PDE5)
|
|
gptkbp:metabolism
|
Liver (CYP3A4, CYP2C9)
|
|
gptkbp:molecularWeight
|
474.58 g/mol
|
|
gptkbp:name
|
gptkb:Sildenafil
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
CHEMBL192
DB00203
135398744
|
|
gptkbp:routeOfAdministration
|
gptkb:Oral
|
|
gptkbp:sideEffect
|
gptkb:Flushing
Headache
Nasal congestion
Visual disturbances
Dyspepsia
|
|
gptkbp:synonym
|
gptkb:Revatio
gptkb:Viagra
|
|
gptkbp:bfsParent
|
gptkb:Celecoxib
gptkb:celecoxib
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
169590-42-5
|